🟢 Ocugen is trading 8% up today in after-hours trading after a $40 million registered direct offering

Ocugen is trading at $1.15 (+7.98%) in after-hours trading after announcing a $40 million registered direct offering.

• The offering sells 20 million shares at $2.00 to one healthcare-focused institutional investor.
• The financing supports late-stage blindness gene-therapy trials and improves near-term funding visibility.
• The rebound follows a 19.92% regular-session decline after uncertainty surrounding interim OCU410ST results, which showed a negative treatment direction in 26 subjects; the trial will continue.